Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P3.13-34 RET Gene, a New Choice for NSCLC

Journal of Thoracic Oncology

English

P2.01-35 Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients With Advanced Lung Cancer

Journal of Thoracic Oncology

English

P2.01-125 EGFR Mutations by NGS in Advanced Squamous Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

Journal of Thoracic Oncology

English

P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

Journal of Thoracic Oncology

English

P3.07-06 Receiving a Diagnosis of MESOthelioma (RADIO Meso): Recommendations for Practice to Improve the Patient Experience

Journal of Thoracic Oncology

English

P1.09-21 Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients

Journal of Thoracic Oncology

English

P2.13-16 Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China

Journal of Thoracic Oncology

English

P008 Correlation Between Genetic Mutation State and Cancer-Associated Thrombosis in Advanced Cancer Patients

Journal of Thoracic Oncology

English

P2.01-64 Prognostic Value of PET-CT After Induction Chemoradiotherapy and Curative Surgery in IIIA-N2 NSCLC: A Multi-Institutional Analysis

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P3.13-34 RET Gene, a New Choice for NSCLC

P2.01-35 Predicting Risk of Chemotherapy-Induced Severe Neutropenia in Patients With Advanced Lung Cancer

P2.01-125 EGFR Mutations by NGS in Advanced Squamous Cell Lung Cancer

P1.01-02 Long-Term Outcomes With First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up From CheckMate 012

P1.01-32 a Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients With Interstitial Lung Disease

P3.07-06 Receiving a Diagnosis of MESOthelioma (RADIO Meso): Recommendations for Practice to Improve the Patient Experience

P1.09-21 Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients

P2.13-16 Preference of Adjuvant Treatments for EGFR-Mutant Resected NSCLC Patients: Results of a National-Wide Survey in China

P008 Correlation Between Genetic Mutation State and Cancer-Associated Thrombosis in Advanced Cancer Patients

P2.01-64 Prognostic Value of PET-CT After Induction Chemoradiotherapy and Curative Surgery in IIIA-N2 NSCLC: A Multi-Institutional Analysis